Marieke Krol

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer
    Marieke Krol
    Institute for Medical Technology Assessment, Erasmus Medical Centre, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Expert Opin Pharmacother 8:1313-28. 2007
  2. doi request reprint Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercises
    Marieke Krol
    Department of Health Policy and Management, Erasmus University Erasmus MC, Rotterdam, The Netherlands
    Value Health 12:172-80. 2009
  3. doi request reprint Productivity costs in economic evaluations: past, present, future
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Pharmacoeconomics 31:537-49. 2013
  4. ncbi request reprint Productivity costs in health-state valuations : does explicit instruction matter?
    Marieke Krol
    Department of Health Policy and Management, Erasmus University Erasmus MC, Rotterdam, The Netherlands
    Pharmacoeconomics 24:401-14. 2006
  5. pmc A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, P O Box 1738, 3000, Rotterdam, The Netherlands
    Eur J Health Econ 17:391-402. 2016
  6. doi request reprint The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses
    Clazien Bouwmans
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands Electronic address
    Value Health 18:753-8. 2015
  7. doi request reprint Altruistic Preferences in Time Tradeoff: Consideration of Effects on Others in Health State Valuations
    Marieke Krol
    Institute of Health Policy and Management MK, AEA, JvE, WB, Erasmus University, Rotterdam, the NetherlandsInstitute for Medical Technology Assessment MK, Erasmus University, Rotterdam, The Netherlands
    Med Decis Making 36:187-98. 2016
  8. doi request reprint Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands
    Soc Sci Med 75:1981-8. 2012
  9. doi request reprint Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands
    Pharmacoeconomics 29:601-19. 2011
  10. doi request reprint Unpaid work in health economic evaluations
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands Electronic address
    Soc Sci Med 144:127-37. 2015

Detail Information

Publications14

  1. ncbi request reprint A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer
    Marieke Krol
    Institute for Medical Technology Assessment, Erasmus Medical Centre, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Expert Opin Pharmacother 8:1313-28. 2007
    ..These studies are preferably performed by taking a societal perspective and including quality of life outcomes...
  2. doi request reprint Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercises
    Marieke Krol
    Department of Health Policy and Management, Erasmus University Erasmus MC, Rotterdam, The Netherlands
    Value Health 12:172-80. 2009
    ..Moreover, it tests the consequences of explicit instructions to include or exclude income effects...
  3. doi request reprint Productivity costs in economic evaluations: past, present, future
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Pharmacoeconomics 31:537-49. 2013
    ..More standardization would increase the comparability and credibility of economic evaluations taking a societal perspective. ..
  4. ncbi request reprint Productivity costs in health-state valuations : does explicit instruction matter?
    Marieke Krol
    Department of Health Policy and Management, Erasmus University Erasmus MC, Rotterdam, The Netherlands
    Pharmacoeconomics 24:401-14. 2006
    ..At the moment, little is known about whether the effects of ill health on income are included in health-state valuations, and how instructions on including or excluding the effects on income influence health-state valuations...
  5. pmc A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, P O Box 1738, 3000, Rotterdam, The Netherlands
    Eur J Health Econ 17:391-402. 2016
    ..This warrants caution in interpreting and comparing the results of these evaluations. ..
  6. doi request reprint The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses
    Clazien Bouwmans
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands Electronic address
    Value Health 18:753-8. 2015
    ..Productivity losses often contribute significantly to the total costs in economic evaluations adopting a societal perspective. Currently, no consensus exists on the measurement and valuation of productivity losses...
  7. doi request reprint Altruistic Preferences in Time Tradeoff: Consideration of Effects on Others in Health State Valuations
    Marieke Krol
    Institute of Health Policy and Management MK, AEA, JvE, WB, Erasmus University, Rotterdam, the NetherlandsInstitute for Medical Technology Assessment MK, Erasmus University, Rotterdam, The Netherlands
    Med Decis Making 36:187-98. 2016
    ..In line with expectations, longevity altruists traded fewer years than quality-of-life altruists. Nonaltruists gave intermediate values...
  8. doi request reprint Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands
    Soc Sci Med 75:1981-8. 2012
    ..Productivity costs estimates are strongly influenced by adjustment for compensation mechanisms and multiplier effects. The validity of such adjustments needs further examination, however...
  9. doi request reprint Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands
    Pharmacoeconomics 29:601-19. 2011
    ..This may considerably bias the results of cost-effectiveness studies, particularly those regarding treatments targeted at diseases with a high incidence rate in the working population, such as depressive disorders...
  10. doi request reprint Unpaid work in health economic evaluations
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands Electronic address
    Soc Sci Med 144:127-37. 2015
    ..Given the strong effects of certain diseases and treatments on the ability to perform unpaid work, unpaid work currently receives less attention in economic evaluations than it deserves. ..
  11. doi request reprint Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Pharmacoeconomics 33:123-35. 2015
    ..These costs and effects of informal caregiving are often excluded in economic evaluations of healthcare interventions. The impact of this exclusion on the outcomes of these evaluations is largely unknown...
  12. doi request reprint How to estimate productivity costs in economic evaluations
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Pharmacoeconomics 32:335-44. 2014
    ..We indicate how to apply the friction cost and the human capital approach and give practical guidance on deriving final cost estimates. ..
  13. doi request reprint Predicting productivity based on EQ-5D: an explorative study
    Marieke Krol
    Department of Health Policy and Management, Erasmus University, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Eur J Health Econ 15:465-75. 2014
    ..Productivity costs are often ignored in economic evaluations. In order to facilitate productivity cost inclusion, it has been suggested to estimate productivity costs indirectly using quality of life data...
  14. ncbi request reprint Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study
    Luciana Scalone
    CIRFF Centre of Pharmacoeconomics, University of Naples Federico II, Naples, Italy CHARTA Foundation member of COPERA, Milan, Italy
    Curr Med Res Opin 24:1905-17. 2008
    ..The purpose was to estimate the societal burden attributable to beta-TM in terms of direct and indirect costs, health-related quality-of-life (HRQoL), satisfaction and compliance with ICT in patients undergoing transfusions and ICT...